用于治疗睡眠障碍（即发作性睡病和发作性嗜睡症）的新型食欲素受体激动剂化合物。
Novel Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy and Hypersomnia.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Jul 3;15(8):1178-1179. doi: 10.1021/acsmedchemlett.4c00285. eCollection 2024 Aug 8.
Abstract
Provided herein are novel compounds as orexin receptor agonists, pharmaceutical compositions, use of such compounds in treating sleep disorders, namely, narcolepsy and hypersomnia, and processes for preparing such compounds.
摘要
本文提供了作为食欲素受体激动剂的新型化合物、药物组合物、此类化合物在治疗睡眠障碍即发作性睡病和发作性嗜睡症中的用途，以及制备此类化合物的方法。
相似文献
1
Novel Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy and Hypersomnia.用于治疗睡眠障碍（即发作性睡病和发作性嗜睡症）的新型食欲素受体激动剂化合物。
ACS Med Chem Lett. 2024 Jul 3;15(8):1178-1179. doi: 10.1021/acsmedchemlett.4c00285. eCollection 2024 Aug 8.
2
Novel Urea-Containing Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy, Hypersomnia, and Sleep Apnea Syndrome.新型含尿素化合物作为食欲素受体激动剂用于治疗睡眠障碍，即发作性睡病、发作性嗜睡症和睡眠呼吸暂停综合征。
ACS Med Chem Lett. 2025 Feb 18;16(3):375-376. doi: 10.1021/acsmedchemlett.5c00067. eCollection 2025 Mar 13.
3
Sulfonamide Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy and Hypersomnia.作为用于治疗睡眠障碍（即发作性睡病和发作性嗜睡症）的食欲素受体激动剂的磺胺类化合物。
ACS Med Chem Lett. 2023 Dec 29;15(1):17-18. doi: 10.1021/acsmedchemlett.3c00546. eCollection 2024 Jan 11.
4
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.新型色胺化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2025 Feb 13;16(3):373-374. doi: 10.1021/acsmedchemlett.5c00047. eCollection 2025 Mar 13.
5
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.新型麦角灵化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
6
A Patient-centric Clinical Trial Design to Comprehensively Evaluate Low-Sodium Oxybate in People with Idiopathic Hypersomnia or Narcolepsy.一项以患者为中心的临床试验设计，旨在全面评估低钠羟丁酸钠在发作性睡病或特发性过度睡眠患者中的疗效。
Neurol Ther. 2025 Jun 9. doi: 10.1007/s40120-025-00745-7.
7
Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.作为用于治疗精神疾病或中枢神经系统疾病的5-HT2A激动剂的新型化合物。
ACS Med Chem Lett. 2025 Feb 11;16(3):377-378. doi: 10.1021/acsmedchemlett.5c00066. eCollection 2025 Mar 13.
8
Novel Ergolines as 5‑HT2A Agonists for Treating Mood Disorders.新型麦角灵类化合物作为5-羟色胺2A受体激动剂用于治疗情绪障碍
ACS Med Chem Lett. 2025 May 21;16(6):974-975. doi: 10.1021/acsmedchemlett.5c00288. eCollection 2025 Jun 12.
9
Novel Phenylalkylamines as 5‑HT2A Agonists for Treating Psychiatric Disorders.新型苯基烷基胺作为治疗精神疾病的5-HT2A激动剂
ACS Med Chem Lett. 2025 May 14;16(6):948-949. doi: 10.1021/acsmedchemlett.5c00269. eCollection 2025 Jun 12.
10
Novel Pyridine Derivatives as 5‑HT2A Agonists for Treating Psychiatric Disorders.新型吡啶衍生物作为治疗精神疾病的5-HT2A激动剂
ACS Med Chem Lett. 2025 May 13;16(6):929-930. doi: 10.1021/acsmedchemlett.5c00244. eCollection 2025 Jun 12.
引用本文的文献
1
Novel Urea-Containing Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy, Hypersomnia, and Sleep Apnea Syndrome.新型含尿素化合物作为食欲素受体激动剂用于治疗睡眠障碍，即发作性睡病、发作性嗜睡症和睡眠呼吸暂停综合征。
ACS Med Chem Lett. 2025 Feb 18;16(3):375-376. doi: 10.1021/acsmedchemlett.5c00067. eCollection 2025 Mar 13.
本文引用的文献
1
The olfactory bulb: A neuroendocrine spotlight on feeding and metabolism.嗅球：一个聚焦于摄食和代谢的神经内分泌点。
J Neuroendocrinol. 2024 Jun;36(6):e13382. doi: 10.1111/jne.13382. Epub 2024 Mar 11.
2
Functions and mechanisms of adenosine and its receptors in sleep regulation.腺苷及其受体在睡眠调节中的功能和机制。
Sleep Med. 2024 Mar;115:210-217. doi: 10.1016/j.sleep.2024.02.012. Epub 2024 Feb 7.
3
Sulfonamide Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy and Hypersomnia.作为用于治疗睡眠障碍（即发作性睡病和发作性嗜睡症）的食欲素受体激动剂的磺胺类化合物。
ACS Med Chem Lett. 2023 Dec 29;15(1):17-18. doi: 10.1021/acsmedchemlett.3c00546. eCollection 2024 Jan 11.
4
Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities.双重食欲素受体拮抗剂在失眠症之外的临床应用：神经和精神共病。
Neuropharmacology. 2024 Mar 1;245:109815. doi: 10.1016/j.neuropharm.2023.109815. Epub 2023 Dec 17.
5
Sleep disorders in Lewy body dementia: Mechanisms, clinical relevance, and unanswered questions.路易体痴呆中的睡眠障碍：机制、临床相关性及未解决的问题。
Alzheimers Dement. 2023 Nov;19(11):5264-5283. doi: 10.1002/alz.13350. Epub 2023 Jul 1.
Zotero 插件